CALUMET ($CLMT) is expected to release its quarterly earnings data on Friday, May 9th before market open, per Finnhub. Analysts are expecting revenue of $909,264,312 and earnings of -$0.58 per share.
You can see Quiver Quantitative's $CLMT stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
CALUMET Insider Trading Activity
CALUMET insiders have traded $CLMT stock on the open market 11 times in the past 6 months. Of those trades, 1 have been purchases and 10 have been sales.
Here’s a breakdown of recent trading of $CLMT stock by insiders over the last 6 months:
- JENNIFER STRAUMINS has made 0 purchases and 4 sales selling 312,861 shares for an estimated $6,498,732.
- STEPHEN P MAWER has made 0 purchases and 4 sales selling 29,594 shares for an estimated $127,230.
- DANIEL L SHEETS sold 3,569 shares for an estimated $75,377
- DANIEL J SAJKOWSKI sold 3,569 shares for an estimated $75,377
- DAVID LUNIN (EVP - CFO) purchased 2,500 shares for an estimated $32,625
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
CALUMET Hedge Fund Activity
We have seen 0 institutional investors add shares of CALUMET stock to their portfolio, and 1 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- IFP ADVISORS, INC removed 2,000 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $44,040
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
CALUMET Analyst Ratings
Wall Street analysts have issued reports on $CLMT in the last several months. We have seen 0 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Sell" rating on 02/04/2025
To track analyst ratings and price targets for CALUMET, check out Quiver Quantitative's $CLMT forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
